Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer

NCT04984096 · clinicaltrials.gov ↗
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Shanghai Chest Hospital